Empirical Financial Services, LLC D.B.A. Empirical Wealth Management Cel Sci Corp Transaction History

Empirical Financial Services, LLC D.B.A. Empirical Wealth Management

$3.55 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$7.1 - $12.82 $94,096 - $169,903	-13,253 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$7.64 - $12.49 $101,230 - $165,492	-13,250 Reduced 49.99%	13,253 $146,000
Q1 2021 May 17, 2021	SELL	$12.0 - $27.64 $40,644 - $93,616	-3,387 Reduced 11.33%	26,503 $403,000
Q2 2020 Aug 12, 2020	BUY	$9.75 - $17.6 $10,530 - $19,008	1,080 Added 3.75%	29,890 $446,000
Q2 2019 Aug 12, 2019	BUY	$3.77 - $8.67 $50,046 - $115,094	13,275 Added 85.45%	28,810 $241,000
Q2 2018 Aug 13, 2018	BUY	$0.92 - $3.5 $3,896 - $14,822	4,235 Added 37.48%	15,535 $14,000
Q4 2017 Feb 12, 2018	BUY	$1.63 - $2.0 $18,419 - $22,600	11,300	11,300 $21,000

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $27.3M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Empirical Financial Services, LLC D.B.A. Empirical Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Empirical Financial Services, LLC D.B.A. Empirical Wealth Management with notifications on news.

Account